Eli Lilly’s rising fortunes tied to its weight loss and diabetes drugs led to a nine-figure payday for its top executive.
Pharmaceutical Technology on MSN8h
Viking strikes $150m deal to secure supply of obesity drugViking Therapeutics has inked a $150m multi-year manufacturing deal with CordenPharma to secure the future supply of its ...
Compounded versions of popular drugs used for weight loss including Wegovy and Zepbound will soon no longer be available ...
Roller-coaster healthcare stock Hims & Hers Health (NYSE: HIMS), whose stock got devastated last week by worries that it ...
Pharmalittle: We’re reading about Lilly and Roche weight loss drugs, FDA and compounders, and more
Three U.S. senators are calling on Robert Kennedy Jr. to disclose what he and President Trump discussed with drugmakers ...
Zacks Investment Research on MSN16h
Eli Lilly Rises 7.5% YTD: Time to Buy, Sell or Hold the Stock?Eli Lilly and Company’s LLY shares dipped almost 5% on Monday after rival Novo Nordisk NVO announced disappointing data from ...
Eli Lilly's stock fell 4.58% following weak trial results from Novo Nordisk’s obesity drug, shaking investor confidence in ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback